Cloud Pharmaceuticals Inc., formerly TeraDiscoveries Inc., is a 21st century bio pharmaceutical company with a unique discovery capability. The company designs and develops new drugs for a wide range of therapeutic areas including cancer, inflammation, CNS disorders, and rare diseases.
Cloud Pharmaceuticals partners extensively throughout its development process. We use our proprietary methods, along with a network of virtual partners, to fill the need that bio/pharma companies have for rapid development of new active molecules.
Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. We accelerate the drug discovery and design process in a way that delivers tangible results and true value for our partners.
The partnership will initially focus on orphan diseases such as Huntington’s disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). In parallel to these efforts, both companies will pursue sponsored development for additional respiratory indications. […]
Cloud Pharmaceuticals and Genomeon Announce Marker Discovery and Drug Design Partnership Relationship to help Cloud Pharmaceuticals identify companion biomarkers effective in targeting cancers and other genetically influenced diseases. […]
Ed Addison, CEO of FFVC’s Cloud Pharmaceuticals, will discuss their revolutionary cloud-based approach to drug design and development at Europe’s leading Biopartnering and Investment Conference in London on May 12th. Addison says “Europe is ahead of the United States in computational drug discovery and design, which is one of the reasons we’re attending BioTrinity.” […]